Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 8:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 457 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Seizures, Epileptic Clear all
Active, not recruiting Phase 3 Interventional

Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures

NCT07505004
View directory record Official record
Conditions
Focal Epilepsy
Interventions
40 mg/day vormatrogine for 12 weeks, 30 mg/day vormatrogine for 12 weeks, 20 mg/day vormatrogine for 12 weeks, Placebo
Drug
Lead sponsor
Praxis Precision Medicines
Industry
Eligibility
18 Years to 85 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
7
States / cities
Miami, Florida • Miami Lakes, Florida • Naples, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 4, 2026, 8:53 PM EDT
Completed Phase 3 Interventional

Pediatric Epilepsy Study

NCT00050947
View directory record Official record
Conditions
Epilepsy
Interventions
oxcarbazepine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Month to 16 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
25
States / cities
Birmingham, Alabama • Mobile, Alabama • Madera, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2011 · Synced Oct 4, 2026, 8:53 PM EDT
Completed No phase listed Observational

Earbud EEG Feasibility Study

NCT05257811
View directory record Official record
Conditions
Epilepsy; Seizure, Sleep
Interventions
NextSense EEG-enabled earbuds
Device
Lead sponsor
NextSense, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Oct 4, 2026, 8:53 PM EDT
Completed Phase 3 Interventional Results available

Progesterone vs Placebo Therapy for Women With Epilepsy

NCT00029536
View directory record Official record
Conditions
Epilepsy
Interventions
Progesterone Lozenges, Matched Placebo Lozenges
Biological · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
13 Years to 45 Years · Female only
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
14
States / cities
Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 4, 2026, 8:53 PM EDT
Completed No phase listed Observational

Monitoring Patients With Uncontrolled Epilepsy

NCT00001149
View directory record Official record
Conditions
Epilepsy, Seizures
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1975 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 4, 2026, 8:53 PM EDT
Terminated Phase 3 Interventional Results available

Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures

NCT04485104
View directory record Official record
Conditions
Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome, Seizure in Participants With Lennox-Gastaut Syndrome
Interventions
GWP42003-P
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Month to 23 Months
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Little Rock, Arkansas • Los Angeles, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 4, 2026, 8:53 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Language and Emotional Function in Patients With Temporal Lobe Epilepsy

NCT00081432
View directory record Official record
Conditions
Epilepsy, Temporal Lobe
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 4, 2026, 8:53 PM EDT
Completed Phase 3 Interventional Results available

A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome

NCT02682927
View directory record Official record
Conditions
Dravet Syndrome, Seizure Disorder
Interventions
ZX008 (Fenfluramine Hydrochloride), Matching Placebo
Drug
Lead sponsor
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Industry
Eligibility
2 Years to 18 Years
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
19
States / cities
Phoenix, Arizona • Tucson, Arizona • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 4, 2026, 8:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Wearable Devices to Monitor Seizures in Autoimmune Epilepsy

NCT05627661
View directory record Official record
Conditions
Autoimmune Epilepsy, Healthy
Interventions
Biosensor
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 4, 2026, 8:53 PM EDT
Enrolling by invitation Phase 3 Interventional

An Open-label Study of XEN1101 in Epilepsy

NCT05718817
View directory record Official record
Conditions
Focal Epilepsy, Tonic-Clonic Seizures
Interventions
XEN1101
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
12 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
54
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 4, 2026, 8:53 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications

NCT02408523
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide Tablet, Lasosamide Oral Solution, Placebo Tablet, Placebo Oral Solution
Drug · Other
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
4 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
27
States / cities
Alabaster, Alabama • Little Rock, Arkansas • Irvine, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 4, 2026, 8:53 PM EDT
Completed Phase 3 Interventional Results available

Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic

NCT01091662
View directory record Official record
Conditions
Epilepsy
Interventions
Eslicarbazepine acetate 1600 mg, Eslicarbazepine acetate 1200 mg
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
39
States / cities
Tucson, Arizona • Conway, Arkansas • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Oct 4, 2026, 8:53 PM EDT
Recruiting Phase 3 Interventional

Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

NCT05219617
View directory record Official record
Conditions
Seizures, Lennox Gastaut Syndrome
Interventions
Carisbamate
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
4 Years to 55 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
22
States / cities
Palo Alto, California • Jacksonville, Florida • Orlando, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 4, 2026, 8:53 PM EDT
Completed Phase 3 Interventional Results available

Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy

NCT00235755
View directory record Official record
Conditions
Seizures
Interventions
Retigabine, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Bethesda, Maryland • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 4, 2026, 8:53 PM EDT
Terminated Not applicable Interventional Results available

Feasibility Study on LITT for Medical Refractory Epilepsy

NCT02820740
View directory record Official record
Conditions
Epilepsy
Interventions
NeuroBlate System
Device
Lead sponsor
Monteris Medical
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Phoenix, Arizona • New Haven, Connecticut • Kansas City, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 4, 2026, 8:53 PM EDT
Completed Phase 3 Interventional

Cenobamate Open-Label Extension Study for YKP3089C025

NCT03961568
View directory record Official record
Conditions
Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsy
Interventions
Cenobamate
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
12 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
16
States / cities
La Jolla, California • Miami, Florida • Tampa, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 4, 2026, 8:53 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

P-glycoprotein Inhibition as Adjunct Treatment for Medically Refractory Epilepsy.

NCT00524134
View directory record Official record
Conditions
Epilepsy
Interventions
Carvedilol-CR
Drug
Lead sponsor
Columbia University
Other
Eligibility
10 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 23, 2016 · Synced Oct 4, 2026, 8:53 PM EDT
Completed Phase 2 Interventional

Hormone Replacement in Menopausal Women With Epilepsy

NCT00027209
View directory record Official record
Conditions
Menopause, Epilepsy
Interventions
prempro
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
0 Years and older · Female only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2006 · Synced Oct 4, 2026, 8:53 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Primary Generalized Tonic-Clonic Seizures (PGTC) Seizures

NCT00104416
View directory record Official record
Conditions
Epilepsy, Tonic-Clonic
Interventions
lamotrigine (LAMICTAL) extended-release, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
13 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
64
States / cities
Anniston, Alabama • Birmingham, Alabama • Northport, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Oct 4, 2026, 8:53 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy

NCT04015141
View directory record Official record
Conditions
Pediatric Epileptic Syndrome, Partial-onset Seizures
Interventions
Perampanel Oral Suspension, Perampanel Tablet
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
1 Month to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
15
States / cities
Los Angeles, California • Aurora, Colorado • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 4, 2026, 8:53 PM EDT
Not listed Not applicable Interventional

Clinical and Electrographic Changes in Responsive Neurostimulation System (RNS) Patients with Acupuncture Treatment

NCT04677751
View directory record Official record
Conditions
Epilepsy
Interventions
Acupuncture intervention
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
15 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 4, 2026, 8:53 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy

NCT03283371
View directory record Official record
Conditions
Epilepsy, Focal Seizures, Partial Seizures
Interventions
Natalizumab, Placebo
Drug · Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 4, 2026, 8:53 PM EDT
Completed Phase 2 Interventional Results available

A Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics in Adolescents

NCT01161524
View directory record Official record
Conditions
Epilepsy
Interventions
Perampanel, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 18 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
11
States / cities
Aurora, Colorado • Gulf Breeze, Florida • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 4, 2026, 8:53 PM EDT
Active, not recruiting No phase listed Observational

Neonatal Seizure Registry, GEnetics of Post-Neonatal Epilepsy

NCT05361070
View directory record Official record
Conditions
Neonatal Seizure, Hypoxic-Ischemic Encephalopathy, Stroke, Intracranial Hemorrhage, Epilepsy, Gene Abnormality
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 4, 2026, 8:53 PM EDT